Mazdutide
Dual GLP-1/Glucagon Receptor Agonist | Weight Reduction & Diabetes
On this page
What is Mazdutide?
Mazdutide is a lab-made peptide modeled on a natural gut hormone called oxyntomodulin, engineered to activate two receptors (GLP-1 and glucagon) at once, which is why it's called a dual agonist. It's an investigational compound studied in Phase 3 trials for metabolic and diabetes research, not yet an FDA-approved medication. Research-grade mazdutide sold here is intended for laboratory research use only — it is not the same product as, and is not a substitute for, an approved medication.
Key terms:
Mazdutide is a dual glp-1/glucagon receptor agonist (synthetic oxyntomodulin analog with fatty-acid conjugation).
Mazdutide (IBI362/LY3305677) is a lab-made version of oxyntomodulin, a natural gut hormone. It was the first of its kind to act on two receptors at once: GLP-1 (a gut hormone that influences appetite and blood sugar) and glucagon (which affects how the body burns energy). Tirzepatide, by contrast, targets GIP and GLP-1. Researchers study the GLP-1 side for reduced appetite and the glucagon side for raising heat production and energy use. The Phase 3 GLORY-1 and GLORY-2 trials reported up to 20% weight reduction. Recent head-to-head trials reported greater effects than semaglutide on blood-sugar control and weight reduction in participants with type 2 diabetes and obesity.
Key research areas
- Up to 20% body weight reduction
- Greater glycemic control reported vs semaglutide in trials
- Increased energy expenditure via glucagon receptor activation
- Improved cardiometabolic markers (BP, lipids, liver fat)
- Once-weekly convenience
Researched dosing
This table reflects how researchers structure mazdutide study designs — the titration schedules and dose ranges used in published trials, presented as research methodology, not personal usage guidance.
| Phase | Dose | Frequency | Route |
|---|---|---|---|
| Weight-reduction studies (3 mg step) | 1.5mg → 3mg | Once weekly | SubQ injection |
| Weight-reduction studies (4.5 mg step) | 1.5mg → 3mg → 4.5mg | Once weekly | SubQ injection |
| Weight-reduction studies (6 mg step) | 2mg → 4mg → 6mg | Once weekly | SubQ injection |
| Weight-reduction studies (9 mg step) | 3mg → 6mg → 9mg | Once weekly | SubQ injection |
| Type 2 diabetes studies (mild-moderate) | 3-4.5mg weekly | Once weekly | SubQ injection |
| Type 2 diabetes with obesity studies | 6-9mg weekly | Once weekly | SubQ injection |
Commonly cycled 60 weeks on, 0+ weeks off.
How it works
At the cell level, mazdutide research looks at how the peptide binds both GLP-1 and glucagon receptors to influence insulin release, digestion speed, and energy expenditure — the terms below are just the names for those cell-signaling steps.
Dual agonist of GLP-1 and glucagon receptors. GLP-1 activation: stimulates insulin release, suppresses glucagon, slows gastric emptying, reduces appetite via hypothalamic signaling. Glucagon activation: increases energy expenditure and thermogenesis, improves hepatic fat metabolism. The dual mechanism provides synergistic weight reduction effects while GLP-1 counteracts glucagon's glucose-raising effects.
Molecular data
These figures — molecular weight, amino-acid sequence, chain length — are the chemistry basics researchers use to confirm a mazdutide sample's identity and purity before it goes into a study.
- Weight
- 4563.1 Da
- Length
- 33 amino acids
- Type
- Oxyntomodulin analog with fatty acid conjugation
33-amino acid linear synthetic peptide conjugated to C20 fatty diacid moiety through hydrophilic linker at Lys20
Research applications
This section lists the research areas — metabolic and diabetes research chief among them — that scientists have studied for mazdutide in Phase 3 trial literature; research-grade mazdutide sold here is intended for laboratory study only, not human use.
Weight Reduction
GLORY-2 trial: 20.1% weight reduction with 9mg dose over 60 weeks. 48.7% of non-diabetic participants achieved ≥20% weight reduction - approaching surgical outcomes. Significant reductions in waist circumference, systolic BP (-7.57 mmHg), diastolic BP (-2.98 mmHg), triglycerides (-43%), LDL cholesterol, and uric acid. Exploratory analysis from GLORY-1 showed 80.2% reduction in liver fat content, suggesting potential MASLD/MASH benefits.
Diabetes
Greater glycemic control reported in head-to-head DREAMS-3 trial vs semaglutide: 48.0% vs 21.0% achieved HbA1c <7.0% AND ≥10% weight reduction. Mean HbA1c reduction -2.03% vs -1.84%.
Cardiovascular
Significant reductions in blood pressure and cardiometabolic markers. Increased heart rate (5-17 bpm) observed but not associated with cardiac events in trials.
Dosage reference
- Doses used in research
- Published trials started at 1.5–3 mg weekly, raising the dose about once a month toward the maintenance dose.
- Frequency in studies
- Same day each week, any time of day
- Handling
- Reconstituted solution — research use only; not for administration
- Timeline reported in studies
- Appetite reduction 1-3 days, weight reduction begins 2-4 weeks, significant results 12-24 weeks, peak effects 48-60 weeks
- Storage
- Lyophilized: -20°C long-term; Reconstituted: 2-8°C use within 30 days
- Cycle length
- 48-60+ weeks for full metabolic benefits based on clinical trials
- Break between cycles
- Medical supervision required - effects diminish gradually after discontinuation
Interactions
This list shows which other metabolic-research peptides scientists study alongside mazdutide, and flags pairings that call for extra caution or monitoring in a research setting.
Reconstitution & storage
This is the standard laboratory method for turning freeze-dried mazdutide powder into a liquid research solution — the same basic water-based mixing process used for most peptide research.
- Remove mazdutide vial from freezer/refrigerator and allow to reach room temperature (15-20 minutes)
- Clean vial top with alcohol swab using circular motion, allow to air dry completely
- Calculate appropriate reconstitution volume based on desired concentration
- Draw calculated amount of bacteriostatic water into syringe, remove air bubbles
- Insert needle at 45-degree angle against vial wall, NOT directly into powder
- Slowly inject BAC water down the side of the vial - drop by drop to prevent foaming
- Remove needle and gently swirl vial in circular motion - NEVER shake vigorously
- Allow solution to sit 2-3 minutes if cloudiness persists, then swirl gently until completely clear
- Final solution should be completely clear and colorless - discard if cloudy or contains particles
- Label vial with reconstitution date and concentration
Lyophilized: -20°C long-term, use within Per manufacturer expiration
Reconstituted: 2-6°C, use within 30 days
Open the Mazdutide reconstitution calculatorQuality indicators
These are the visual and lab-report checks researchers use to confirm a mazdutide sample is pure and correctly identified before it goes into a study — a quick sanity check against the Certificate of Analysis (COA), not a guarantee.
White to off-white lyophilized powder - Properly freeze-dried mazdutide appears as light, fluffy powder without clumping or discoloration
Clear reconstituted solution - Should be completely clear and colorless after proper reconstitution - no visible particles
Intact vial seal and labeling - Rubber stopper intact, clear mg dosage, batch numbers, and expiration dates visible
Proper storage conditions maintained - Stored at correct temperature, protected from light, no freeze-thaw cycles
Source verification - Mazdutide is primarily available from research chemical suppliers. Verify purity testing and source reputation
Clumping, discoloration, or moisture - Powder should not be clumped, yellow/brown colored, or show signs of moisture damage
Persistent cloudiness or particles - Cloudiness or visible particles after proper reconstitution indicates degradation - do not use
What to expect
This timeline reflects what the Phase 3 trial literature reports at each study stage — research context for comparing studies, not a personal-results promise.
Appetite reduction, possible mild nausea, decreased portion sizes
Early weight reduction begins (1-2%), improved satiety after meals
Dose escalation phase, GI symptoms typically improving, 3-5% weight reduction
Steady weight reduction continues (7-12%), energy expenditure effects evident
Significant weight reduction (12-17%), metabolic markers improving
Peak effects (up to 20% weight reduction), sustained improvements in BP, lipids, glucose
Safety notes
This section summarizes mazdutide's regulatory status and handling notes — it remains an investigational compound with no FDA approval, and this context is provided for laboratory researchers, not medical guidance.
- Not recommended during pregnancy or breastfeeding - insufficient safety data
- Caution with personal/family history of medullary thyroid carcinoma or MEN2 syndrome
- If taking insulin or sulfonylureas, monitor blood glucose closely and reduce doses as needed
- Monitor for signs of pancreatitis - severe persistent abdominal pain radiating to back
- Not FDA-approved - investigational drug in Phase 3 clinical trials
Regulatory status
- Not approved by the FDA for any indication.
- Supplied and described for laboratory research use only — not for human or veterinary use.
Community data
Community Insights
Based on data the community reported. Not clinical proof.
Frequently asked questions
What is Mazdutide?
Mazdutide (IBI362/LY3305677) is a lab-made peptide modeled on a natural gut hormone called oxyntomodulin, engineered to activate two receptors at once — GLP-1 and glucagon — which is why researchers call it a dual agonist. It is an investigational compound studied in Phase 3 trials rather than an approved medication. Lux BioPure supplies research-grade mazdutide strictly for laboratory study, not for use in people or animals.
What class of compound is mazdutide?
Mazdutide is classified as a synthetic oxyntomodulin analog with fatty-acid conjugation that acts as a dual GLP-1 and glucagon receptor agonist. In the research literature it is described as a 33-amino-acid linear peptide with a molecular weight near 4,563 daltons — figures lab technicians use to confirm a sample's identity and purity before it enters a study.
How is mazdutide typically reconstituted for research use?
In the laboratory, a mazdutide vial is brought to room temperature and its top cleaned with an alcohol swab. Bacteriostatic water is injected drop by drop down the vial wall — not onto the powder — to prevent foaming, then the vial is gently swirled, never shaken, until the solution is completely clear and colorless. This is standard peptide-handling methodology, not a usage instruction.
How should mazdutide be stored in the lab?
Lyophilized mazdutide is best held at around -20°C for long-term storage, protected from light and kept free of freeze-thaw cycles. Once reconstituted with bacteriostatic water, the solution is refrigerated near 2–6°C and typically used within about 30 days, with the vial labeled by date and concentration. A good sample is a white, fluffy powder that yields a clear, colorless solution.
Is mazdutide legal to purchase for research in Canada?
Lux BioPure sells mazdutide in Canada strictly as a research-use-only chemical for laboratory study — it is not for human or veterinary use and is not offered as a drug or supplement. Mazdutide is not FDA-approved; it remains an investigational drug in Phase 3 clinical trials, and the research-grade material here is not a substitute for an approved medication.
References
First Phase 3 weight management trial showing clinically meaningful weight reductions with once-weekly mazdutide. Both doses achieved significant weight reduction vs placebo with favorable safety profile.
View StudyHigh-dose 9mg mazdutide achieved 20.1% weight reduction in non-diabetic participants vs 2.8% placebo. 48.7% achieved ≥20% weight reduction. No plateau observed through week 60.
View StudyMazdutide outperformed semaglutide on the primary endpoint - 48.0% vs 21.0% achieved HbA1c <7.0% AND ≥10% weight reduction (p<0.0001). Mean HbA1c reduction -2.03% vs -1.84%.